Living longer, healthier lives has become a global growth market. Behind the capsules and powders marketed under the banner of “longevity” lies sophisticated process engineering. Solutions will be on display at numerous booths at POWTECH TECHNOPHARM in Nuremberg from September 29 to October 1, 2026. For manufacturers of active pharmaceutical ingredients as well as for machinery and plant engineering companies, this opens a market that is still in the early stages of its industrial maturity.

Aging begins at the cellular level. And every cell is a tiny factory with its own power plant, quality control, and recycling facility. Over the years, efficiency declines: power plants falter, waste removal stalls, and spent cells remain on site, disrupting operations. The longevity trend therefore doesn’t start with wrinkles and gray hair, but with the maintenance of the cell itself.

From a Niche Topic to a Billion-Dollar Market

Just a few years ago, “longevity” was a term confined to research labs and California startups. Today, it has become a consumer goods segment experiencing double-digit growth. According to a market study by The Business Research Company, the market for longevity supplements – that is, dietary supplements aimed at healthy aging and cellular function – alone is projected to rise from $8.8 billion in 2025 to $14.3 billion in 2030. If we broaden the market definition to include anti-aging medications, diagnostics, and wellness, forecasts suggest that market volumes will exceed $60 billion over the coming decade.

The most important driver is demographics: The World Health Organization (WHO) estimates that the number of people aged 60 and older worldwide will rise from about one billion in 2020 to approximately 1.4 billion in 2030. Added to this is a shift in mindset. Consumers are increasingly investing in prevention rather than treatment; they are thinking in terms of healthy life years (“healthspan”) rather than just lifespan.

For the process industry, it is not so much the medical hype that is of interest as the question behind it: How are these products actually made? This is where things get exciting for visitors and exhibitors at POWTECH TECHNOPHARM.

The active ingredients and what connects them in terms of process engineering

Four classes of active ingredients dominate the market. NMN (nicotinamide mononucleotide) is a precursor to the coenzyme NAD⁺, which plays a central role in cellular metabolism. Spermidine, found in wheat germ and soybeans, is considered a driver of the cell’s own “garbage disposal” system.

Urolithin A, which is produced in the gut during the breakdown of pomegranate and walnut compounds, is said to trigger the renewal of the cell’s “powerhouses,” the mitochondria. Added to this is the rapidly growing group of senolytics, which are designed to specifically remove old, non-dividing cells from tissue, as well as other NAD⁺ boosters.

What these substances have in common from a process engineering perspective is not their biochemistry, but their production logic. All four represent a shift away from an unreliable, microbiome- or plant-dependent “natural” formation toward controlled, reproducible industrial manufacturing of defined quality. And all four ultimately undergo the same basic process engineering operations that constitute the core business of POWTECH TECHNOPHARM: chemical or biocatalytic reaction, separation and purification, drying into a storage-stable solid, as well as formulation and filling usually as a powder, granule, or capsule.

A clear example is urolithin A: The substance is produced in the human body only if the appropriate gut flora is present – which is not the case for a large portion of the population. Anyone who still wants to reliably offer urolithin A in a defined dose and purity must manufacture it industrially, independent of the microbiome. The Swiss manufacturer Amazentis has described to the U.S. Food and Drug Administration (FDA) a clearly specified manufacturing process for its product Mitopure, featuring high purity urolithin A (purity >97 %), defined limits for impurities, and a final drying step to produce the powder. What began as a metabolic coincidence thus becomes a standardized ingredient in powder form, exactly the kind of challenge for which plant engineers provide process and handling solutions.

Three Paths to the Same Molecule

The process engineering challenge becomes particularly clear when considering NMN. Here, three manufacturing routes are competing in parallel for industrial dominance. Classic chemical synthesis relies on aggressive reagents and precise temperature and humidity control, a complex and expensive process. Microbial fermentation uses genetically engineered bacteria but still struggles with low yields and the problem that common host organisms produce endotoxins, which must be laboriously removed.

The most promising approach at present is enzymatic cascade biocatalysis: multiple tailor-made enzymes convert inexpensive starting materials into the target molecule in a single reaction vessel. The advantages from a process engineering perspective are obvious: mild reaction conditions, high purity, and an aqueous system without the need for complex moisture control. This approach, which marks the actual leap in innovation, is explored in greater depth in a separate article in the Industry Insights section of POWTECH TECHNOPHARM.

In the case of spermidine, extraction from wheat germ, fermentation, and chemical synthesis compete with one another – a textbook example of how the same target substance can be produced via completely different process chains. Which route prevails depends not only on chemistry but also on cost, scalability, and regulatory approval.

The Real Bottleneck: Purification and Formulation

For machinery and plant manufacturers, the opportunity lies not only in the reaction itself but also in the steps that follow. Purification – filtration, chromatography, separation – accounts for a significant portion of manufacturing costs in fermentative and biocatalytic processes, often 15 to 25 percent, and is considered a key bottleneck when scaling up from the laboratory to the production scale. Interesting developments are currently emerging in this area: continuous chromatography and membrane-based separation processes promise significant cost advantages over traditional batch processes. Modular, flexibly configurable plant designs shorten the time to market.

Formulation is at least as important. A highly pure active ingredient is of little use if it breaks down in the digestive tract before it can take effect. That is why techniques are employed that are at the heart of POWTECH TECHNOPHARM: spray drying and microencapsulation for stabilization, liposomal encapsulation for better absorption, along with gentle processes such as spray cooling for temperature-sensitive substances. Wall materials, particle size distribution, flowability, and compressibility for tableting are classic challenges of mechanical and thermal process engineering – only now applied to a new, high-margin product class.

Longevity active ingredients are high-quality solids that must be handled, dosed, mixed, granulated, dried, and filled under GxP conditions, often in small batches, with high purity requirements, and sometimes under containment, because the substances are valuable and, in some cases, highly active. As a result, this topic addresses nearly the entire spectrum of exhibitors at the trade show: from reactor and fermenter construction to centrifuges, filters, and drying systems, as well as mixing, granulation, and tableting technology, containment solutions, and analytics.

Regulations Set Limits

Despite the sense of optimism, a sober assessment is warranted. The regulatory framework in Europe is demanding: NMN, for example, is classified as a “novel food” in the EU and cannot be readily marketed without the appropriate authorization, whereas spermidine-rich wheat germ extract is already approved. For manufacturers, this means that the choice of process and regulatory approval are closely linked. Health-related advertising claims are strictly regulated. And the market forecasts, as enticing as they may sound, are primarily based on commercial studies using varying methodologies – they indicate a trend, not a certainty.

It is this blend of genuine growth and ongoing industrialization that makes the topic attractive to exhibitors and visitors at POWTECH TECHNOPHARM. Longevity is not a mature market where processes have long since been optimized, but rather a field in which active ingredient manufacturers and plant engineers are still jointly developing their solutions. Those exhibiting in Nuremberg or wandering through the halls will find here less of a trendy topic and more of a concrete challenge: turning promising biochemistry into reproducible, safe, and affordable products. This is, in the best sense of the word, a process engineering challenge.

Integrating Experimental and Data Science Capabilities

Under the terms of the agreement, Odyssey Therapeutics will utilize Evotec’s proprietary drug discovery platform. This platform combines extensive compound libraries and advanced screening capabilities with machine learning-driven analysis and AI-enabled data science technologies. By leveraging high-throughput experimentation alongside data-driven insights, the companies seek to discover and validate differentiated small molecule drug candidates across multiple high-value targets.

The approach is designed to accelerate the identification of validated hit series and support the swift progression of early-stage research programs into potential therapeutic options.

Strategic Alignment and Discovery Goals

Speaking on the strategic approach, Evotec Chief Scientific Officer Cord Dohrmann, PhD, noted that drug discovery increasingly relies on uniting deep disease biology with modern experimental platforms.

“This collaboration with Odyssey illustrates well Evotec’s strategy in applying integrated discovery platform technologies to complex disease areas,” Dohrmann stated. “We aim to generate differentiated, validated starting points for Odyssey to develop into new therapies for autoimmune and inflammatory diseases.”

Through this partnership for autoimmune and inflammatory diseases, both organizations aim to combine complementary technological and scientific capabilities to enhance early-stage drug development. The effort focuses on delivering scalable starting points aimed at advancing future inflammatory disease treatments.

Structure of the Financial Agreement

While specific financial figures were not disclosed, the agreement establishes that Evotec is eligible for milestone payments tied to performance. These payments are contingent upon the successful delivery of validated hit series for each specified target, structuring the collaboration to link value creation directly to drug discovery achievements through their shared drug discovery platform.

Expanding Technological Integration Across Scientific Teams

Under the new arrangement, BMS scientific teams will scale the use of Schrödinger technologies, including the Bunsen AI co-scientist platform and RetroSynth, an AI-driven synthesis planning system. The collaboration aims to enable researchers to explore chemical space more extensively, prioritize molecular candidates with increased confidence, and support decision-making in the early stages of drug discovery.

Bunsen is designed as an agentic AI co-scientist tailored to perform complex workflows in molecular design and computational research. It carries out Schrödinger’s physics-based computational methods, conducts planning and interpretation tasks, and integrates with other research technologies. Complementing this, RetroSynth enables high-throughput evaluation of chemical synthesis planning pathways to evaluate candidate structures efficiently.

Statements from Leadership

Robert Abel, chief scientific officer of the Schrödinger platform, said, “BMS is a long-standing customer and collaborator, and they have been an industry leader in integrating computation into drug discovery. We are thrilled they are deploying Bunsen at a large scale. Adopting Bunsen and our computational platform at scale will empower a broader group of scientists to embrace a predict-first computational approach.”

Stephen Johnson, vice president of computational sciences at BMS, said, “Over the past several years, AI has become a key enabler for our scientists, allowing them to scale their creativity and scientific expertise across our research organisation. Bunsen is another capability we are adding to that toolkit, one that allows our scientists to think differently about how physics-based tools can be used to navigate molecular design space and accelerate the discovery of innovative medicines for patients.”

Core Capabilities and Recent Computational Developments

Schrödinger’s software platform combines artificial intelligence with physics-based simulation to support hypothesis evaluation and synthetic feasibility in molecular research. The organization’s computational solutions are licensed by entities across the global pharmaceutical, biotechnology, industrial, and academic sectors.

According to industry sources, leading domestic pharmaceutical companies have recently secured product approvals as well as large-scale supply agreements across major Latin American countries, including Brazil and Mexico. The portfolio of products being introduced into the region continues to expand beyond aesthetic and plastic surgery offerings such as botulinum toxin to include prescription medicines and advanced digital healthcare solutions. This broader product mix reflects the growing importance of the Latin American market in the overseas expansion strategies of South Korean pharmaceutical companies.

Companies Broaden Regional Footprint Through Local Partnerships

Dongkook Pharmaceutical is moving into the Latin American prescription drug segment with an incrementally modified new drug combination product. The company signed a license and supply agreement with Spanish pharmaceutical company Faes Farma for the benign prostatic hyperplasia treatment ‘Uresco Tablets’. The contract is worth a total of W3.90 billion ($2.83 million) over the next 10 years. Under the agreement, the company plans to sequentially launch the product in 13 Latin American countries including Mexico and Chile and target the local chronic disease market.

Daewoong Pharmaceutical is also strengthening its presence in the Latin American market through its self-developed botulinum toxin product ‘Nabota’. In January, the company reinforced its regional position by signing an export contract for Mexico worth W2.95 billion ($2.14 million) with Latin American partner M8. As a result, Nabota has established a presence across all five of Latin America’s leading aesthetic and plastic surgery markets, including Brazil, Argentina, and Colombia. The company has also expanded its prescription drug business in the region after its diabetes treatment ‘Enblo’ received product approval in Mexico, increasing the number of Latin American countries where the treatment has obtained approval to seven.

Expansion efforts are extending beyond conventional pharmaceuticals into digital healthcare technologies. Dong-A ST entered into a distribution agreement with Cardios, a Brazilian company specializing in cardiac monitoring, for the wearable remote patient monitoring solution ‘HiCardi Plus’. The patch-type solution is capable of measuring electrocardiograms and respiration in real time and is scheduled to be supplied throughout Brazil using local hospital sales networks.

Industry sources indicate that the approach adopted by Korean pharmaceutical companies for the Latin American market has shifted significantly from simple export-driven business models toward locally embedded strategies. Rather than relying solely on overseas shipments, companies are increasingly collaborating with partners that possess extensive knowledge of local market conditions. This strategy enables them to navigate regulatory requirements more effectively while simultaneously establishing distribution infrastructure that supports faster market entry.

Metabolic diseases, including obesity and diabetes, have reached pandemic proportions, straining healthcare systems and diminishing the quality of life for a significant portion of the global population. The physiological role of GLP-1 is multifaceted; it stimulates insulin secretion, suppresses glucagon release, and slows gastric emptying, all while signaling the brain to increase feelings of satiety. Pharma Advancement notes that by mimicking this natural hormone, GLP-1 drugs have demonstrated remarkable efficacy in reducing blood sugar levels and inducing substantial weight loss. The transition to oral formulations is not merely a matter of convenience; it is a fundamental pharmaceutical innovation that addresses the deep-seated psychological and logistical hurdles associated with chronic injectable therapies.

The Challenge of Oral Peptide Delivery

To understand the significance of oral GLP-1 drugs, one must appreciate the immense scientific challenge of delivering peptides via the gastrointestinal tract. Peptides are essentially chains of amino acids, and the human stomach is a highly hostile environment designed specifically to break these chains down. Acidic gastric juices and proteolytic enzymes typically destroy peptides long before they can reach the bloodstream. For a GLP-1 agonist to be effective in pill form, it must survive this digestive gauntlet and penetrate the intestinal lining with enough bioavailability to achieve a therapeutic effect.

The solution to this problem has come in the form of innovative chemical carriers and novel molecular engineering. One of the most notable successes in this field involves the use of SNAC (sodium salcaprozate), a small-molecule absorption enhancer that temporarily raises the local pH in the micro-environment of the stomach. This localized pH shift prevents the acidic degradation of the peptide, allowing the medication to be absorbed directly through the gastric mucosa. While the bioavailability of oral peptides remains significantly lower than that of their injectable counterparts, the ability to deliver a consistent, daily supra-physiological dose via a tablet has opened a new chapter in metabolic disease therapy.

Furthermore, ongoing drug development is now branching into two distinct paths. The first involves optimizing these peptide-carrier combinations to improve absorption and reduce the variability caused by food intake. The second path is the development of non-peptide, small-molecule GLP-1 receptor agonists. Unlike peptides, these small molecules are inherently stable in the digestive system and do not require specialized carriers for absorption. These next-gen oral GLP-1 drugs could potentially offer higher bioavailability and simpler manufacturing processes, making them even more attractive for large-scale global distribution. The focus is not just on making a pill, but on making a pill that is as robust and reliable as any other standard medication in a patient’s cabinet.

Impact on Patient Compliance and Obesity Treatment

The shift toward oral GLP-1 drugs is expected to have a profound impact on patient compliance and the overall trajectory of obesity treatment. In the context of chronic disease, adherence is the single most important factor in achieving long-term health outcomes. Many patients suffer from needle phobia or find the logistics of storing and disposing of injectable pens to be cumbersome. By offering a daily pill that can be taken alongside other common medications, healthcare providers can lower the threshold for starting treatment. This is particularly important for obesity, which is often under-treated due to the stigma and the perceived intensity of existing medical interventions.

Furthermore, the oral format allows for more flexible dosing strategies. Injectables are often administered weekly, which can lead to fluctuations in drug levels and potential side effects as the body adjusts to each dose. A daily oral tablet provides a more steady state of the medication in the bloodstream, which may improve tolerability for some patients. As the medical community increasingly recognizes obesity as a chronic, relapsing metabolic disease rather than a failure of willpower, the availability of oral GLP-1 drugs provides a practical and sustainable tool for long-term management. This transition is not just about weight loss; it is about reducing the incidence of co-morbidities like cardiovascular disease, sleep apnea, and fatty liver disease.

Pharmaceutical Innovation and Market Dynamics

The race to dominate the market for oral GLP-1 drugs has spurred unprecedented competition among global pharmaceutical giants. The potential market for these medications is estimated to be in the tens of billions of dollars, reflecting the vast unmet need in metabolic health. Companies are not just competing on delivery methods but also on the potency of the molecules. We are now seeing the development of multi-receptor agonists, often called twincretins or triple G agonists, which target GLP-1 along with other hormones like GIP (glucose-dependent insulinotropic polypeptide) and glucagon.

When these multi-hormone agonists, such as the promising Triple G agonists like Retatrutide, are successfully formulated into oral GLP-1 drugs, the clinical results could be even more dramatic than the successes we see today. The ultimate goal of current drug development is to match, or even exceed, the weight-loss efficacy of bariatric surgery through a simple, once-daily pill. Achieving a 20% to 25% reduction in total body weight via pharmacotherapy would represent a paradigm shift in how we approach metabolic health on a population scale. It would move obesity from the realm of surgical intervention into the realm of primary care management, similar to how statins transformed the treatment of high cholesterol.

However, this wave of pharmaceutical innovation also brings significant challenges related to manufacturing and global supply chains. The production of peptides in the massive quantities required for daily oral dosing is significantly more complex and resource-intensive than the production of once-weekly injectables. A daily oral dose requires a much larger amount of the active pharmaceutical ingredient (API) due to the lower bioavailability. This has led to concerns about peptide shortages and the ability of the industry to scale production to meet the skyrocketing global demand. Ensuring that these life-saving innovations remain affordable, accessible, and equitably distributed is a critical challenge that will require collaboration between the pharmaceutical industry, healthcare providers, and global policymakers.

The Societal and Economic Implications of Metabolic Health

The widespread adoption of oral GLP-1 drugs will likely have ripple effects far beyond the walls of the clinic. Obesity and its related conditions are major drivers of healthcare spending, productivity loss, and disability. By providing a scalable and effective means of managing these conditions, the new generation of GLP-1 therapies could lead to a significant reduction in the global burden of metabolic disease. This could translate into billions of dollars in savings for national health systems and improved economic participation for millions of individuals.

Moreover, the psychological impact of moving away from the willpower myth of weight loss cannot be overstated. By framing obesity as a biological condition that can be treated with a pill, these drugs are helping to dismantle the pervasive stigma that has long surrounded the disease. This cultural shift, combined with the ease of use of oral medications, may encourage more people to seek help earlier in their disease progression. As we look toward the 2030s, the legacy of oral GLP-1 drugs will likely be measured not just in pounds lost or blood sugar lowered, but in the fundamental reorganization of how society values and protects metabolic health.

Future Outlook: Beyond Diabetes and Obesity

Pharma Advancement believes that the potential applications for oral GLP-1 drugs may extend far beyond their current indications for diabetes and obesity. Emerging research suggests that GLP-1 receptors are present in many parts of the body, including the brain, heart, and kidneys. There is significant interest in the potential of these drugs to treat neurodegenerative conditions like Alzheimer’s and Parkinson’s disease, where they may exert neuroprotective effects. Additionally, the anti-inflammatory properties of GLP-1 agonists are being investigated for the treatment of non-alcoholic steatohepatitis (NASH) and chronic kidney disease.

The transition to oral delivery makes these broad applications much more feasible. It is far more practical to prescribe a daily pill for a neurodegenerative condition or a chronic inflammatory disease than it is to require lifelong weekly injections. As our understanding of metabolic health continues to deepen, we may find that metabolic disease therapy becomes a cornerstone of preventative medicine. In this future, oral GLP-1 drugs could be used not just to treat existing illness but to optimize metabolic function and extend the healthy lifespan of the general population. The journey from the lab to the pharmacy shelf is long and arduous, but the progress made in the last decade suggests that the best is yet to come.

In 2026, POWTECH TECHNOPHARM will once again offer ample opportunities for interdisciplinary and international dialogue. In this context, various industry associations are providing inspiration with sessions and events promoting knowledge transfer, networking, and process safety. Delegates at the International Meeting of Bulk Solids Associations on Tuesday, 29 September from 10:00 to 11:00 (NCC Ost, Level 2, New Delhi Room) will gain valuable insights into overseas markets. Representatives of associations from Germany, the UK, the Netherlands and Japan will provide information about business and partnership opportunities. Moreover, the DSIV Process Solutions Pavilion at Booth 7-857 in Hall 7 offers various opportunities to learn about the innovative bulk solids technologies available from DSIV (German Powder and Bulk Association) member companies.

The VDMA Special Show (Booth 7-776 in Hall 7) will feature joint exhibits by its Air Handling Technology and Process Plant and Equipment associations and their member companies. Under the banner “Clean Air – Smart Processing”, the focus this year will be on sustainable, low-emission production and smart, digitally-assisted processing.

Another visitor drawcard that is sure to go off with a bang is the twice-daily live demonstration of dust explosion protection. At midday and in the afternoon, the Rembe Research + Technology Center and the IND EX® Association will carry out impressive demonstrations of the effects of a dust explosion and discuss explosion protection systems. At the IND EX® Explosion Safety Forum from 9:30 to 12:30 on Thursday, 1 October (NCC Ost, Level 2, Riga Room), international specialists can look forward to in-depth professional discussions in an informative programme addressing topics such as practical explosion protection, standards, and new scientific insights from large-scale explosion tests.

Pavilions address growth markets

This year, three pavilions will focus on recycling, pharmaceutical processing technology, and networking with players from key markets like South America and Asia. The pavilion format is well-established at POWTECH TECHNOPHARM and offers an uncomplicated way of participating for exhibitors wishing to showcase their expertise in a particular area in a suitable environment. The Pharma-in-Focus Pavilion is a hub for expertise in pharmaceutical process technology, while the Recycling-in-Focus Pavilion addresses the growing importance of the circular economy and the technologies needed to support it. At the PROCESSING ALLIANCE Pavilion, visitors can network with exhibitors from POWTECH TECHNOPHARM-affiliated events in Brazil, Greece and China while forging international contacts.

Technical innovation takes centre stage at the Young Innovators Pavilion, where startups and fledgling companies showcase their organizations and solutions.

Expert Forum the hub for inspirational ideas, innovations and discussions

The EXPERT FORUM presentations begin every day at 10:00 in Hall 7, Booth 7-489. On Tuesday morning, Wednesday afternoon, and Thursday from 11.30, the focus is on pharmaceutical processing topics. During the sessions, which are moderated by the institutional sponsor of POWTECH TECHNOPHARM, APV (International Association for Pharmaceutical Technology), pharmaceutical industry insiders and experts from various exhibiting companies address a wide range of topics including the characterisation of pharmaceutical materials, virtual planning and optimisation, the use of AI in maintenance, and pharmaceutical freezing processes. Other presentations in the EXPERT FORUM are devoted to overarching issues such as the future of processing, safety and security, smart industry, plant engineering and process technology, and sustainability and energy efficiency. Participants will also gain insights into sustainable energy supply, optimising material flow for tomorrow’s production environment, and AI-assisted machine diagnosis and process management.

From 13:00 to 14:00 on Thursday, the stage is given over to young professionals. At this session organised by the kjVI, the VDI’s network of creative young process engineers, Ida Tolksdorf and Pauline Rust from the VAA (Association of Chemical Industry Managers) will provide tips on first career steps and employment contracts (in German). These presentations are part of the Student Day, which is geared towards all those currently studying or starting out in their careers and is accompanied by special guided tours by the kjVI and young professionals from the DSIV (German Powder and Bulk Association). Students, who enjoy free entry to the fair on Student Day, will learn about innovative technology and the relevant companies from the processing environment, and will have the opportunity to chat with industry experts.

WOMEN4PROCESSING networking event goes into its second round

The WOMEN4PROCESSING networking format for women in the processing industry, which made its debut last year, is now taking place for the second time. Since its launch, women working in industry, academia, R&D, marketing and sales have been able to network through WOMEN4PROCESSING – both online in the associated LinkedIn group and in person again at POWTECH TECHNOPHARM on Wednesday 30 September from 15:30 to 17:00. Prospective members are warmly invited to join the LinkedIn group ahead of the fair to get involved in discussions and obtain their invitation to the next networking meeting.

Good planning is the key to a successful trade fair visit

POWTECH TECHNOPHARM will exhibit a wide range of technologies for processing powders, solids and liquids, including solutions for the GxP-compliant manufacture of pharmaceuticals. Visitors can use the Exhibitor and Product Database beforehand to find relevant products and plan an efficient exhibition walkabout. The results can be filtered not just by product category but also, e.g., by user industry and the various special shows. Information on the programme for the EXPERT FORUM and other highlights is available on the POWTECH TECHNOPHARM website. The wish list function can provide an overview of all relevant exhibitors and topics.

The signing of the agreement boosting Egyptian pharma export took place during an official visit by a high-level Djiboutian delegation led by Hibo Bacha, Chairperson of Bacha Group, Vice Chairperson of the Egyptian-Djiboutian Business Council, and President of the Djiboutian Businesswomen Association. Bilateral talks centered on advancing strategic cooperation in healthcare, reinforcing historic diplomatic ties, and supporting sustainable development initiatives across the continent.

Strategic Accord to Enhance Regional Pharmaceutical Security

As part of the delegation’s itinerary, Gypto Pharma demonstrated its integrated manufacturing infrastructure and modern production facilities. These sites operate in full compliance with international quality benchmarks and Good Manufacturing Practices (GMP). Delegations from both sides evaluated the specific healthcare requirements of Djibouti and neighboring countries to facilitate product registration and enable the direct distribution of essential pharmaceuticals.

Beyond pharma export agreements, the discussions outlined plans to gradually localize selected components of the pharmaceutical manufacturing process. This effort will leverage Bacha Group’s established logistics and industrial center in Djibouti, aiming to reinforce regional supply chains, optimize value chains, and promote deeper industrial integration.

Manufacturing Integration and Direct Supply Expansion

The strategic Partnership utilizes Djibouti’s position as a trade and logistics gateway connecting African, Arab, and global markets. This location serves as an entry point for delivering Egyptian medicines to member states of the Intergovernmental Authority on Development (IGAD) and the broader Horn of Africa.

Amr Mamdouh, Chairperson and Managing Director of Gypto Pharma City, stated that the Gypto Pharma Partnership is a key step in expanding Egyptian-African industrial ties. He emphasized that delivering safe and effective treatments forms the bedrock of healthcare security, identifying Djibouti as a pivotal regional trade partner.

Hibo Bacha commended the technological and manufacturing standards at Gypto Pharma, noting that the agreement supports the delivery of reliable healthcare solutions to East Africa. She added that both organizations aim to convert the memorandum into operational projects that strengthen economic collaboration and long-term pharmaceutical security.

AstraZeneca currently has a market capitalization of approximately 196 billion pounds (approximately 377 trillion Korean won), making it the second-largest listed company on the UK stock market after HSBC, while BMS has a market capitalization of approximately 133 billion dollars (approximately 190 trillion Korean won). Reports indicate that both companies have been holding merger discussions over recent months. Although negotiations could result in an agreement in the near future, there is also the possibility that talks may be delayed or ultimately fail. The structure of the proposed transaction has yet to be finalized, though a combination of cash and stock payments is regarded as the most likely approach for the USD 400B merger.

Combined Cancer Portfolio Would Strengthen Global Market Position

Both AstraZeneca and BMS have built their growth strategies around anticancer drugs, making oncology a central focus of the proposed combination. AstraZeneca’s portfolio includes lung cancer treatment ‘Tagrisso’, breast cancer treatment ‘Enhertu’, and immune-oncology drug ‘Imfinzi’, among others. BMS markets immune-oncology drugs ‘Opdivo’ and ‘Yervoy’, among others. If the companies proceed with the USD 400B merger, the combined business would hold a dominant market share and an extensive pipeline of new drug candidates in the global anticancer drug market.

AstraZeneca was previously the target of a takeover attempt by U.S. Pfizer in 2014, when Pfizer proposed an acquisition valuing the company at approximately 70 billion pounds. AstraZeneca rejected that offer and has since experienced rapid growth driven by its anticancer medicines, reaching an enterprise value approaching 200 billion pounds. Last year, AstraZeneca generated global sales of 58.7 billion dollars and is targeting annual sales of 80 billion dollars by 2030. Nearly half of its current total sales originate from the U.S., the world’s largest pharmaceutical market, and a merger with BMS would further reinforce its business presence there. Meanwhile, BMS continues to face medium- to long-term sales declines resulting from patent expirations of key medications. Although it acquired biotech company Celgene for 74 billion dollars in 2019, the anticipated benefits have not been fully realized, leaving the company seeking new growth drivers and an expanded pipeline of new drugs.

Competition Authorities Expected to Closely Scrutinize Proposed Deal

The most significant challenge facing the proposed USD 400B merger is expected to come from antitrust reviews by competition authorities across multiple countries. Regulatory concerns are likely because the two companies have substantial overlap in their anticancer drug businesses. In particular, BMS’s Opdivo and AstraZeneca’s Imfinzi directly compete in the treatment of non-small cell lung cancer. As a result, competition authorities are expected to closely examine whether combining the two pharmaceutical companies could reduce competition within specific therapeutic markets before any merger is allowed to proceed.

The framework builds upon WHO’s Greener pharmaceuticals’ regulatory highway call to action, introduced in 2024, following an extensive process involving evidence gathering and consultations with regulatory authorities, manufacturers, international organizations, standards-setting bodies and technical experts from around the world. It highlights how regulators can utilize existing tools—including standards, scientific guidance, reliance, digital transformation and innovative regulatory pathways—to encourage wider adoption of lower-carbon technologies while continuing to safeguard patients.

Dr. Rogério Gaspar, Director of WHO’s Department of Regulation and Prequalification, said, “The question is no longer whether pharmaceutical decarbonization is possible. The real challenge is how quickly and equitably we can make it a reality.”

“This framework demonstrates how medicines regulators can create the conditions for innovation to flourish while continuing to uphold the highest standards of quality, safety and efficacy. By making full use of existing regulatory tools, they can help advance more sustainable pharmaceutical systems that benefit both people and the planet,” he added.

Framework Outlines Regulatory Measures To Support Lower–Carbon Pharmaceutical Systems

WHO noted that health systems account for around 5% of global greenhouse gas emissions, with pharmaceutical products contributing significantly throughout their lifecycle, including raw material sourcing, manufacturing active ingredients, packaging, distribution, use and disposal. At the same time, climate change continues to disrupt health systems and pharmaceutical supply chains globally. Recognizing that many technologies and solutions required for pharmaceutical decarbonization are already available, the framework emphasizes creating regulatory conditions that encourage broader and more consistent adoption without introducing delays, fragmented requirements or barriers to access.

To achieve this, the framework is structured around three interconnected pillars:

• The first focuses on awareness and capacity building by encouraging climate literacy within existing regulatory training programmes and improving regulators’ ability to identify emissions hotspots across pharmaceutical portfolios while strengthening knowledge exchange through existing global and regional regulatory networks.
• The second pillar addresses guidance, tools and standards by recommending stronger international alignment in measuring, reporting and comparing pharmaceutical emissions through recognized standards, common methodologies and voluntary reporting mechanisms to improve transparency, consistency and reduce duplication for regulators and manufacturers.
• The third pillar concentrates on innovation and innovative regulatory pathways through expanded digital regulatory services, greater access to early scientific advice, streamlined sustainability-related post-approval changes, collaborative regulatory approaches and stronger reliance mechanisms, allowing environmentally beneficial innovations to move more efficiently through regulatory systems without compromising oversight.

Implementation Strategy Prioritizes Collaboration, Equity and Global Participation

The framework is the outcome of literature reviews, stakeholder consultations, horizon scanning and discussions held during WHO’s Global Regulators Summit in June 2026. These activities established broad international agreement that pharmaceutical decarbonization will require coordinated efforts involving regulators, manufacturers, procurement agencies, governments, standards-setting bodies, multilateral organizations, researchers and civil society.

Rather than establishing new institutions, WHO intends to implement the framework through existing international and regional platforms while working closely with national regulatory authorities, regional networks, the International Coalition of Medicines Regulatory Authorities, the International Council for Harmonisation and other partners to encourage knowledge sharing, pilot initiatives and greater regulatory alignment.

WHO further emphasized that the transition towards greener pharmaceuticals should remain just and inclusive through capacity building, technology transfer, sustainable financing and international collaboration. Looking ahead, the organization will continue working with regulators and partners worldwide to implement the framework through pilot projects, updated guidance, strengthened reliance mechanisms, capacity building and continued international dialogue to ensure future health products remain safe, effective, accessible and aligned with the goals of a healthier planet.

Pharma Advancement notes that the evolution of GLP-1 drugs beyond weight loss is driven by a deepening understanding of the GLP-1 receptor’s distribution throughout the human body. While the initial focus was on the pancreas and the brain’s appetite centers, researchers have identified these receptors in the heart, kidneys, liver, and even the central nervous system. This biological map has opened the floodgates for drug development, leading to a surge in clinical trials designed to test the efficacy of these molecules against a spectrum of diseases that, on the surface, seem unrelated to blood sugar or body mass index. In 2026, the medical community is witnessing the fruition of these efforts as regulatory bodies and clinical guidelines expand to include indications that were once considered outside the scope of incretin-based therapies.

The Cardiovascular Renaissance

Perhaps the most significant expansion of GLP-1 drugs beyond weight loss is occurring within the realm of cardiovascular health. For years, the primary goal of heart disease management was the control of cholesterol and blood pressure. However, the results of massive cardiovascular outcomes trials have repositioned GLP-1 drugs as foundational tools for reducing major adverse cardiovascular events (MACE). In 2026, cardiologists are increasingly prescribing these medications not just for their metabolic benefits but for their direct cardioprotective effects.

The mechanism is multifaceted. Beyond the indirect benefits of weight reduction and improved glycemic control, GLP-1 receptor agonists appear to improve endothelial function, reduce systemic inflammation, and even modulate the heart’s utilization of energy. Clinical data has shown a marked decrease in the risk of stroke and myocardial infarction in non-diabetic populations, a finding that has fundamentally altered the standard of care. This transition is particularly evident in the treatment of heart failure with preserved ejection fraction (HFpEF), a condition that long lacked effective pharmacological options. By addressing the systemic inflammation and metabolic dysfunction that often underpin HFpEF, GLP-1 drugs have filled a critical therapeutic void, offering patients a path toward improved exercise capacity and quality of life.

Transforming the Landscape of Chronic Kidney Disease

The intersection of metabolic disease and renal health has historically been a site of significant clinical frustration. Chronic kidney disease (CKD) often progresses silently, frequently leading to dialysis or transplantation. However, 2026 stands as a turning point in nephrology, largely due to the integration of GLP-1 drugs into renal protection protocols. Early results from landmark trials, such as the FLOW study, demonstrated that semaglutide could reduce the risk of kidney disease progression and renal death by nearly a quarter.

This nephroprotection is not merely a byproduct of lowered blood pressure. The presence of GLP-1 receptors in the proximal tubules of the kidney suggests a direct interaction that reduces oxidative stress and fibrosis. For patients with type 2 diabetes and comorbid CKD, these drugs have become a cornerstone of therapy, often used in conjunction with SGLT2 inhibitors to create a dual-pillar approach to kidney preservation. The expansion into non-diabetic CKD is the next frontier, with clinical trials in 2026 actively exploring how pharmaceutical innovation can decouple these renal benefits from the drug’s original glucose-lowering intent.

The Rise of MASH and Liver Health

Metabolic-associated steatohepatitis (MASH), formerly known as NASH, has become one of the leading causes of liver transplantation worldwide. Characterized by fat accumulation, inflammation, and progressive scarring, MASH has historically been treated with lifestyle modification—a recommendation that often proves insufficient for advanced cases. The arrival of next-generation GLP-1 drugs, particularly those that also target glucagon and GIP receptors, has changed the prognosis for millions.

In 2026, the clinical focus has shifted toward dual and triple agonists like survodutide and tirzepatide, which have shown remarkable ability to reduce liver fat content and, in some cases, reverse fibrosis. These advances in drug development are particularly exciting because they address the root cause of the metabolic disease rather than just the symptoms. By optimizing the liver’s metabolic environment, these drugs help prevent the progression to cirrhosis and hepatocellular carcinoma. The pharmaceutical market in 2026 reflects this shift, with MASH emerging as a primary indication that justifies the high cost of these therapies for insurers and healthcare systems.

Navigating the Neuro-Frontier: Parkinson’s and Alzheimer’s

The most debated and high-stakes expansion of GLP-1 drugs involves the central nervous system. The brain-gut axis is no longer a theoretical concept but a clinical target. Researchers have long noted that patients with metabolic dysfunction have a higher risk of neurodegenerative diseases, leading to the hypothesis that GLP-1 drugs might offer neuroprotective benefits. In 2026, the results of this research are presenting a nuanced picture.

While early trials in Alzheimer’s disease, such as the EVOKE series, faced challenges in meeting primary endpoints across broad populations, they have provided invaluable data on how these drugs modulate neuroinflammation. In contrast, the application of GLP-1 receptor agonists in Parkinson’s disease has shown significant promise. Drugs like lixisenatide have demonstrated the potential to slow the progression of motor symptoms by protecting dopaminergic neurons from inflammatory damage. This highlights a shift in drug development toward disease-modifying rather than merely symptom-managing neurology. Even where trials have been mixed, the 2026 perspective is one of refinement—identifying the specific sub-populations and stages of disease where metabolic intervention can most effectively halt cognitive or motor decline.

Sleep Apnea and the Resolution of Obstructive Disorders

The relationship between obesity treatment and obstructive sleep apnea (OSA) is well-documented, but 2026 has seen GLP-1 drugs receive specific clinical indications for this condition. For many patients, OSA is a mechanical issue driven by excess tissue in the airway, but it is also a metabolic issue characterized by systemic inflammation and altered respiratory drive. The SURMOUNT-OSA trials provided the clinical evidence necessary to prove that GLP-1 drugs can reduce the apnea-hypopnea index (AHI) by over 60% in many individuals.

This has profound implications for cardiovascular health, as untreated sleep apnea is a major driver of hypertension and arrhythmias. By addressing OSA through pharmacological means, clinicians in 2026 are able to offer an alternative or an adjunct to CPAP machines, which often suffer from low patient compliance. This represents a holistic approach to metabolic disease, where a single molecule can simultaneously address weight, blood pressure, and sleep architecture.

Addiction and the Dopamine Reward Pathway

One of the more unexpected developments in 2026 is the emerging use of GLP-1 drugs in treating addictive disorders. Anecdotal evidence from early adopters of semaglutide suggested a significant reduction in cravings for alcohol, nicotine, and even impulse shopping. Rigorous clinical trials are now catching up to these observations. By modulating the dopamine reward pathways in the brain’s ventral tegmental area, GLP-1 drugs appear to quiet the noise of addictive impulses.

This indicates a future where drug development for substance use disorders might pivot toward metabolic pathways. While still in the early stages of broad clinical adoption, the potential for GLP-1 drugs beyond weight loss to tackle the opioid crisis or alcohol use disorder is a major topic of discussion at medical congresses in 2026. It underscores the drug’s role as a systemic regulator of human behavior and biology, rather than just a tool for calorie restriction.

The Pharmaceutical Innovation of 2026: Multi-Agonists and Delivery

As clinical indications expand, so too does the technology behind the drugs. The 2026 pharmaceutical market is characterized by a move away from simple GLP-1 mono-therapy toward multi-agonists. These ‘triple G’ molecules—targeting GLP-1, GIP, and glucagon receptors—provide a more potent metabolic signal, allowing for better efficacy in difficult-to-treat conditions like advanced MASH or severe obesity-related heart failure.

Furthermore, the innovation in delivery systems has addressed one of the biggest hurdles to widespread adoption: the needle. Oral formulations and long-acting monthly injectables have become standard, improving patient adherence and expanding the drug’s reach into primary clinical care. This accessibility is crucial as the list of indications grows. A drug that can treat a dozen different chronic conditions is only useful if patients can maintain the regimen over decades.

Ethical and Economic Considerations in a New Era

The rapid expansion of GLP-1 drugs into so many areas of medicine brings significant economic challenges. In 2026, the conversation has moved from should these drugs be used to how can every person in need afford to use them. With indications now spanning heart, kidney, liver, and brain health, the potential patient pool is enormous. This has led to a restructuring of insurance models, where the high upfront cost of the medication is weighed against the massive long-term savings of preventing dialysis, heart transplants, and nursing home care for neurodegenerative conditions.

There is also a human element to this shift. Patients who previously felt stigmatized by the use of weight loss drugs now find themselves taking a metabolic stabilizer that protects their heart and kidneys. This change in framing is essential for patient dignity and for the integration of these therapies into routine clinical care. The professional insight of 2026 recognizes that obesity was never a siloed condition, but a central node in a web of systemic dysfunction.

The landscape of 2026 is defined by a sense of cautious optimism. While the magic pill narrative is always dangerous in medicine, the data supporting the systemic benefits of GLP-1 drugs is increasingly difficult to ignore. From the stabilization of renal function to the reduction of neuroinflammation, these molecules are proving that the human body’s metabolic and inflammatory systems are inextricably linked. Pharma Advancement believes that the role of GLP-1 drugs will likely only continue to grow, cementing their place as one of the most versatile and impactful classes of medication in the history of modern pharmacology.